Navigation Links
Drugs & Bugs: A New App from Monthly Prescribing Reference
Date:2/23/2012

NEW YORK, Feb. 23, 2012 /PRNewswire/ -- Monthly Prescribing Reference (MPR) is pleased to announce the launch of the Drugs & Bugs App, an essential resource for healthcare professionals. The app provides comprehensive information on antibiotic spectrum of efficacy against microorganisms. Clinicians may use the searchable alpha indices or search drugs and bugs by bacterial class or pharmacological class to begin their query.

The Drugs & Bugs App features:

  • A database of more than 100 antibiotics and nearly 200 bacterial pathogens
  • Smart Search capability by pathogen, type of infection, brand and generic drug names
  • Quick-to-read results on spectrum of activity
  • Comprehensive drug monographs for anti-infective agents
  • Useful comparative charts by drug class
  • Clinical calculators

Drugs & Bugs was developed by MPR and US Biomedical Information Systems (USBMIS), MPR's app development partner, in cooperation with Philip Chung, PharmD, BCPS; Clinical Pharmacy Manager in Infectious Diseases at Montefiore Medical Center, NY. The drug monographs are frequently updated and reviewed by MPR's team of pharmacists and physicians.

"Choosing an empiric antibiotic regimen can be daunting," said Dr. Chung. "The Drugs & Bugs App is a useful tool for selecting empiric antibiotic regimens before susceptibility results become available. The app also aids clinicians in the selection of antibiotic regimens with the narrowest spectrum possible based on susceptibility results." 

Drugs & Bugs is now available for Apple iOS (iPhone, iPad, iPod Touch) and Android (Android phones and tablets, Kindle Fire, NOOK) platforms and can be downloaded at empr.com/drugsandbugs, the iTunes App Store, Android Market, Amazon Appstore, and NOOK Apps.

"The innovative use of our drug information content to create new and useful products for clinicians is integral to our digital strategy," said Tammy Chernin, VP, MPR Drug Information & Product Development. "The need to limit the development of resistance with the judicious use of antibiotics is of paramount importance. The Drugs & Bugs App is a fantastic example of MPR's commitment to providing clinicians with tools that support their prescribing decisions."

Dr. Darwin Ang, MD, PhD, MPH agreed.  Dr. Ang, founder of USBMIS, said, "MPR already provides a great product, and they are strongly committed to using the latest technology, as in the Drugs & Bugs App, to disseminate their crucial data."

For more than 26 years, healthcare professionals in the United States have relied on the print editions of MPR to deliver up-to-date, concise drug information at the point-of-care. That same drug information is also available online, as well as on mobile devices and smartphones, and has been enhanced with digital clinical tools and resources. The pharmacist-editors at MPR are dedicated to bringing the highest quality drug information to all clinicians, with the most powerful and flexible clinical decision support tools available.

About MPR and Haymarket Media Inc.

Monthly Prescribing Reference is published by Haymarket Media Inc. (HMI), a global publication and communications company with operations on five continents. Founded in 1957 and headquartered in the United Kingdom, HMI publishes titles in 23 languages in more than 100 nations. In the United States HMI publishes a number of healthcare journals, including MPR (primary care and specialty editions), The Clinical Advisor, and Renal & Urology News. Since 1985, MPR has been the most widely used drug reference by healthcare professionals in a wide variety of specialties and practice settings. 


'/>"/>
SOURCE Monthly Prescribing Reference
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
4. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
5. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... JOLLA, Calif. , Dec. 6, 2016 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development ... new drug development candidates at its R&D day, ... The first candidate, RGLS5040, is an anti-miR targeting ... The second candidate, RGLS4326, is an anti-miR targeting ...
(Date:12/6/2016)... new study released today by the Alliance for ... Drug Pricing Program will continue to expand at an unprecedented ... exceed $23 billion in total purchases at the 340B price. ... Part B drug reimbursement purchases over the next five years. ... of data on total drug purchases through 340B from 2005 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... ODU, a worldwide leader in ... its advanced highly customizable contact technology solutions. , ODU Single Contact Technology portfolio ... ideal for a wide range of applications that require customization from industries like ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving ... are not fortunate enough to receive bountiful gifts wrapped tightly under a Christmas Tree. ... to the children of the world. , In exchange for generous donations, customers will ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Facial plastic surgeon, ... holiday season by donating a portion of proceeds to two local organizations: North Chicago ... Animal Control & Friends is a team of authorized and trained volunteers who ...
(Date:12/7/2016)... , ... December 07, 2016 , ... "ProBrand Flip allows ... all media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip ... to use drop zones. Editors can select from a variety of flip book animations. ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
Breaking Medicine News(10 mins):